Keryx Biopharmaceuticals, Inc. Announces First Quarter 2012 Financial Results - $KERX

Keryx Biopharmaceuticals, Inc. Announces First Quarter 2012 Financial Results - $KERX

NEW YORK, May 8, 2012 /PRNewswire/ -- Keryx Biopharmaceuticals, Inc. (KERX), a biopharmaceutical company focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of renal disease (the "Company"), today announced its results for the first quarter ended March 31, 2012.

At March 31, 2012, the Company had cash, cash equivalents, interest receivable, and investment securities of $31.0 million, as compared to $39.5 million at December 31, 2011.

The net loss for the first quarter ended March 31, 2012 was $9.1 million, or $0.13 per share, compared to a net loss of $6.4 million, or $0.10 per share, for the comparable quarter in 2011, representing an increase in net loss of $2.7 million.  Other research and development expenses, for the first quarter ended March 31, 2012, increased by $2.5 million, as compared to the first quarter of 2011, principally related to the KRX-0401 (perifosine) and Zerenex Phase 3 clinical programs.  The net loss for the first quarter ended March 31, 2012, included $0.6 million of non-cash compensation expense related to equity incentive grants.

On May 4, 2012, the Company executed a License Termination and Technology Transfer Agreement with Aeterna Zentaris GmbH ("Zentaris"), whereby the license agreement for KRX-0401 (perifosine) was terminated, and in exchange for the transfer of the U.S. Investigational New Drug Application, development data, intellectual property and contracts to Zentaris, Keryx shall receive a royalty on future net sales of perifosine in the U.S., Canada and Mexico.  Zentaris has assumed all costs related to the Perifosine program going forward.

Ron Bentsur, the Company's Chief Executive Officer, said,

"Though we were disappointed with the recent negative outcome of the perifosine Phase 3 study in colorectal cancer, we remain excited by the prospects of the Zerenex opportunity as a treatment for hyperphosphatemia.  Following two successful short-term Phase 3 studies of Zerenex, in the U.S. and Japan, we look forward to the completion of the Phase 3 clinical programs in the U.S. and Japan by year-end, and the potential New Drug Application filings in the U.S., Europe and Japan within less than  twelve months." 

He continued,

"Our financial position remains strong and we believe that we have sufficient capital to take us beyond the anticipated NDA filings for Zerenex."

The Company will host an investor conference call tomorrow, Wednesday, May 9, 2012, at 8:30am EDT, to discuss the Company's first quarter financial results and provide a business outlook for the remainder of 2012.           

In order to participate in the conference call, please call 1-877-869-3847       (U.S.), 1-201-689-8261 (outside the U.S.), call-in ID: KERYX. The audio recording of the conference call will be available for replay at http://www.keryx.com, for a period of 15 days after the call.

Read the full press release here